Viking Therapeutics, Inc.

VKTX

US92686J1060

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 03:23:20 2024-07-12 pm EDT			5-day change	1st Jan Change
57.64 ^USD	-1.69%		+12.21%	+209.13%

Jul. 01	Viking Therapeutics, Inc.(NasdaqCM:VKTX) added to Russell 1000 Dynamic Index	CI
Jul. 01	Viking Therapeutics, Inc.(NasdaqCM:VKTX) added to Russell Midcap Growth Index	CI

Viking Therapeutics, Inc.(NasdaqCM:VKTX) added to Russell Midcap Index

July 30, 2024

Latest news about Viking Therapeutics, Inc.

Viking Therapeutics, Inc.(NasdaqCM:VKTX) added to Russell 1000 Dynamic Index	Jun. 30	CI
Viking Therapeutics, Inc.(NasdaqCM:VKTX) added to Russell Midcap Growth Index	Jun. 30	CI
Viking Therapeutics, Inc.(NasdaqCM:VKTX) added to Russell 1000 Index	Jun. 30	CI
Viking Therapeutics, Inc.(NasdaqCM:VKTX) dropped from Russell 2000 Growth Index	Jun. 30	CI
Viking Therapeutics, Inc.(NasdaqCM:VKTX) dropped from Russell 2000 Index	Jun. 30	CI
Viking Therapeutics, Inc.(NasdaqCM:VKTX) dropped from Russell 2000 Dynamic Index	Jun. 30	CI
Viking Therapeutics, Inc.(NasdaqCM:VKTX) added to Russell Midcap Index	Jun. 30	CI
Viking Therapeutics, Inc.(NasdaqCM:VKTX) added to Russell 1000 Growth Index	Jun. 30	CI
Morgan Stanley Initiates Viking Therapeutics at Overweight With $105 Price Target	Jun. 27	MT
Viking Therapeutics, Inc. Presents Preclinical Data on Novel Dual Amylin and Calcitonin Receptor Agonists At 84th Scientific Sessions of the American Diabetes Association	Jun. 24	CI
Health Care Climbs on Defensive Bias - Health Care Roundup	Jun. 04	DJ
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday	Jun. 04	MT
Viking Therapeutics Reports 'Positive' 52-Week Results for NASH Drug; Shares Rise Pre-Bell	Jun. 04	MT
Transcript : Viking Therapeutics, Inc. - Special Call	Jun. 04
Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2B Voyage Study of Vk2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis	Jun. 04	CI
Raymond James Upgrades Viking Therapeutics to Strong Buy From Outperform	May. 17	MT
North American Morning Briefing : The "Everything -2-	May. 17	DJ
Viking Therapeutics Insider Sold Shares Worth $4,986,008, According to a Recent SEC Filing	May. 06	MT
Wall St set to open sharply higher on soft jobs data	May. 03	RE
Amgen shares jump after teasing weight-loss drug data, rivals slip	May. 03	RE
Viking Therapeutics Insider Sold Shares Worth $22,136,474, According to a Recent SEC Filing	May. 03	MT
Sector Update: Health Care Stocks Lean Lower Pre-Bell Thursday	Apr. 25	MT
Tranche Update on Viking Therapeutics, Inc.'s Equity Buyback Plan announced on April 27, 2022.	Apr. 25	CI
Viking Therapeutics Q1 Loss Widens; Shares Fall After Hours	Apr. 24	MT
Transcript : Viking Therapeutics, Inc., Q1 2024 Earnings Call, Apr 24, 2024	Apr. 24

Chart Viking Therapeutics, Inc.

Duration

Period

More charts

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for treatment of metabolic and endocrine disorders. The Company's clinical programs include VK2809, an orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is being evaluated in a Phase II b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. The Company is developing VK0214, which is also an orally available, tissue and receptor-subtype selective agonist of TRb for X-linked adrenoleukodystrophy (X-ALD), a rare X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. It is also developing VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the treatment of various metabolic disorders.

Sector

Biotechnology & Medical Research

Calendar

2024-07-23 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

58.63 USD

Average target price

112.1 USD

Spread / Average Target

+91.16%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VIKING THERAPEUTICS, INC.	+209.13%	6.47B
VERTEX PHARMACEUTICALS INCORPORATED	+20.35%	127B
REGENERON PHARMACEUTICALS, INC.	+25.34%	117B
ARGENX SE	+25.56%	27.77B
BIONTECH SE	-19.84%	20.44B
GENMAB A/S	-14.36%	16.62B
BEIGENE, LTD.	-14.50%	15.92B
WUXI APPTEC CO., LTD.	-46.67%	14.94B
NEUROCRINE BIOSCIENCES, INC.	+12.15%	14.74B
SAREPTA THERAPEUTICS, INC.	+57.04%	14.38B

Bio Therapeutic Drugs